Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
about
How I treat pediatric acute myeloid leukemiaChildhood acute myeloid leukaemiaImpact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology GroupEthnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology GroupRandomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study.Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a paediatric oncology group study.NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.Management of relapsed acute myeloid leukaemia.Recent advances in management of acute leukaemia.Hematopoietic stem cell transplantation for leukemiaClassification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia.Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia.Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99.Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis.Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemiaAcute myeloid leukemia in children: a review of risk factors and recent trials.Glucocorticoid resistance in childhood leukaemia: mechanisms and modulation.Recent advances in the treatment of infant acute myeloid leukemia.Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.Life-threatening and fatal infections in children with acute myeloid leukemia: a report from the Children's Oncology Group.Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia.Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era.Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.Treatment of childhood acute myeloid leukemia.Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelaeIncidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador.Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trialClinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.Gastrointestinal complications in children with acute myeloid leukemia.Pediatric acute myeloid leukemia.Improved outcome in pediatric AML due to augmented supportive care.Novel therapies for children with acute myeloid leukaemia.Current treatment and outcome for childhood acute leukemia in Tanzania.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.
P2860
Q26992280-0F8EE1D5-1200-4055-A317-F98432AC142DQ27005960-E410F4F0-887D-4758-9A16-99A9E91FB706Q28755379-810F2888-1685-4920-8911-2303C5B937FEQ30444713-AA055F8A-9942-42FB-9600-578BB473F0EDQ30444746-AC449CCF-4A47-4CD1-96B1-C08399F8FB1FQ33248188-5A5B0BAA-36C5-4216-8D76-F38CFDC122EAQ33338463-C6F71886-976C-4E7E-86EB-59D4F5FCBE4BQ33400806-F91FAE52-B192-43D8-9E9A-027C55612643Q33710760-DB1530CD-F242-4C73-8BAE-DA754DED7564Q33751243-970917A9-8093-4073-9856-7495213BD056Q33930802-9BD59B85-CD79-47F3-ACDB-C8162AD37564Q34034180-2165A1D0-CD16-4856-9B48-F0F6D528AB7FQ34071693-BF687609-DA47-4100-99C9-2C5C4DCD3494Q34079823-78784786-3CBB-43C2-AE03-3F45C5430E4EQ34172042-0353339B-BD16-4FC4-AA4A-CFA1DBCC6C08Q34579668-6E014699-9807-4265-BE95-F9CE0E1DF6A6Q34679596-E4F3060F-E814-43C7-A25A-59AEDE6C9C8BQ34742630-E2CE8487-5380-43DD-9DB6-7DB96CB7EF23Q35008310-847C9FA2-292A-4657-9015-1D5B06CE8C51Q35089181-CC00C63D-FFB7-4361-9797-62AA147F7916Q35152603-76D11998-3B76-4E8D-A120-627F3F1A7BADQ35209900-4684761B-AA25-4745-9A5A-188C1742FF6FQ35643005-D46F0BB5-627E-447D-BB11-76FF3852530FQ35668858-DB03B322-3DD0-460B-BA8D-3B5FC707A6F5Q35814611-CF5D52E5-1497-42C6-8DA8-3A1123726A5FQ35921471-31CD1E8D-8FDC-4DEC-ABCC-DE9300549CACQ36097750-A6778D08-F909-47B9-BE39-8854190D9BE9Q36246359-D0607A81-AC48-456B-9661-4D4ED1BE930EQ36284532-B328379A-B8DA-4F61-B705-34AE9123C5D3Q36661874-029A598C-AE2D-44BF-9CC2-BAE9CE2770ADQ37160666-5DD72188-609E-4BC7-A12B-58E25087AF5FQ37303824-17BE7021-2330-4C94-869A-D0EBF09AB5C6Q37323006-11EE558D-5B42-4842-AC30-734E4D2EDD95Q37347515-F610343D-45AE-4A32-8E86-D60427DAB982Q37720759-FF59F21A-CF1E-412C-9141-EEDFD10B4475Q37988570-01CB4CBC-D5CA-410F-819A-56B184F0E4EFQ38012400-213DF4E8-9974-4799-AD3A-3E426FF2B8B5Q38096798-075C4B13-93FA-42DB-8AED-14B3C85B88C1Q38137995-6469D8BA-382E-441F-A17B-337D85C228FCQ38196743-2F8681AC-8474-48FD-B705-7821D245378D
P2860
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Marked improvements in outcome ...... dhood Leukaemia Working Party.
@en
Marked improvements in outcome ...... dhood Leukaemia Working Party.
@nl
type
label
Marked improvements in outcome ...... dhood Leukaemia Working Party.
@en
Marked improvements in outcome ...... dhood Leukaemia Working Party.
@nl
prefLabel
Marked improvements in outcome ...... dhood Leukaemia Working Party.
@en
Marked improvements in outcome ...... dhood Leukaemia Working Party.
@nl
P2093
P2860
P1476
Marked improvements in outcome ...... ldhood Leukaemia Working Party
@en
P2093
P2860
P304
P356
10.1046/J.1365-2141.1998.00677.X
P407
P50
P577
1998-04-01T00:00:00Z